Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Decreases By 23.3%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the recipient of a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 4,600 shares, a decline of 23.3% from the September 15th total of 6,000 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 26,800 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Barinthus Biotherapeutics in a research report on Thursday, September 26th. Alliance Global Partners lowered their price target on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a report on Tuesday, August 13th.

Barinthus Biotherapeutics Stock Up 2.6 %

NASDAQ:BRNS traded up $0.03 during trading hours on Tuesday, reaching $1.20. The company had a trading volume of 5,802 shares, compared to its average volume of 22,958. The firm has a market cap of $46.84 million, a price-to-earnings ratio of -0.64 and a beta of -0.53. The business’s 50-day simple moving average is $1.26 and its two-hundred day simple moving average is $1.76. Barinthus Biotherapeutics has a twelve month low of $1.11 and a twelve month high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01). As a group, equities analysts predict that Barinthus Biotherapeutics will post -1.71 earnings per share for the current year.

Institutional Trading of Barinthus Biotherapeutics

Several hedge funds have recently bought and sold shares of the business. Catalina Capital Group LLC acquired a new position in shares of Barinthus Biotherapeutics during the second quarter valued at about $25,000. Ipswich Investment Management Co. Inc. acquired a new position in Barinthus Biotherapeutics during the 2nd quarter valued at about $32,000. BlueCrest Capital Management Ltd bought a new stake in Barinthus Biotherapeutics during the 1st quarter worth approximately $1,292,000. DC Funds LP bought a new stake in Barinthus Biotherapeutics during the 1st quarter worth approximately $1,528,000. Finally, Alphabet Inc. purchased a new stake in shares of Barinthus Biotherapeutics in the second quarter worth approximately $2,119,000. Institutional investors and hedge funds own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.